Adaptive Biotechnologies applies immune-system sequencing to diagnostics and research, profiling T-cell and B-cell receptors at scale. Its clonoSEQ assay is used to measure minimal residual disease in certain blood cancers, and the company also partners on drug discovery and immune-medicine tools. The business sits at the intersection of next-generation sequencing and clinical immunology rather than traditional small-molecule drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 52.4 | — | -29.9 | — |
| Q2 2025 | 58.9 | — | -25.6 | — |
| Q3 2025 | 94 | — | 9.6 | — |
| Q4 2025 | 71.7 | — | -13.6 | — |
| Q1 2026 | 70.9 | 35.1% | -20 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AXT, Inc. (AXTI), iRhythm Holdings, Inc. (IRTC), CVB Financial Corp. (CVBF), IDEAYA Biosciences, Inc. (IDYA), Grand Canyon Education, Inc. (LOPE), Tango Therapeutics, Inc. (TNGX)